Artificial Tyroserleutide Transporters for Synergistic Cancer Therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Nanotechnology

Background:

• Peptide transporters are crucial for cellular uptake of small peptides, impacting nutrient absorption, immune response, and signaling.
• Transporting charge-neutral peptides, which are polar and aggregate easily, presents a significant challenge for artificial systems.
• Existing methods struggle with efficient and targeted delivery of neutral peptides.

Purpose of the Study:

• To develop a novel artificial peptide transporter system for charge-neutral peptides.
• To investigate the efficacy of a molecular tweezer, 5F-C12, in facilitating transmembrane transport of neutral peptides.
• To evaluate the impact of 5F-C12 on the bioavailability and anticancer activity of tyroserleutide.

Main Methods:

• Design and synthesis of a novel molecular tweezer, 5F-C12, with integrated anion and cation transport functionalities.
• Formation of a stable 1:1 complex between 5F-C12 and the neutral peptide tyroserleutide.
• Assessment of transmembrane transport efficiency using EC50 values and evaluation of anticancer effects in vitro and in vivo.

Main Results:

• 5F-C12 successfully formed a stable 1:1 complex with tyroserleutide, a neutral peptide.
• The molecular tweezer actively facilitated transmembrane transport, achieving an EC50 of 7.5 μM.
• Significant enhancement in tyroserleutide's bioavailability and potent anticancer effects against MCF-7 breast cancer cells were observed.

Conclusions:

• 5F-C12 represents a novel class of artificial peptide transporters capable of overcoming challenges associated with neutral peptide delivery.
• This system demonstrates potential for improving the therapeutic efficacy of peptide-based drugs, such as the anticancer agent tyroserleutide.
• The findings open new avenues for developing advanced drug delivery systems for challenging peptide therapeutics.